Share this article

According to GlobalData, TELEPORT is one of 67 product lines sold in the US cardiac catheters market; these product lines are sold by 17 different manufacturers. The average selling price for TELEPORT increased in hospitals, decreased in health systems, and increased outside of hospital facilities in 2022. The price of the TELEPORT device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Cardiac Catheters - OrbusNeich - TELEPORT

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.

In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as OrbusNeich apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.

OrbusNeich overview

OrbusNeich is a medical device company that designs, develops, manufactures and markets medical devices for vascular intervention. The company concentrates on the development of cardiology devices for the treatment of vascular diseases. It provides products such as bio-engineered stents, dual therapy stents, pro-healing stents, bare metal stents and balloons, among others. OrbusNeich’s dual therapy stent, which features its proprietary EPC Capturing Technology, is designed to repair blood vessel injury and regenerate endothelium. The company’s customer base consists predominantly of interventional cardiologists. The company operates through offices, production and research facilities, and distributors in the Americas, Asia Pacific, Europe, Middle East and Africa. OrbusNeich is headquartered in Hong Kong.

For a complete picture of TELEPORT, Cardiac Catheters pricing in the US, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.